Joe
09-17-2007, 08:20 AM
The U.S. Food and Drug Administration today approved Evista (raloxifene hydrochloride) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
More... (http://www.news-medical.net/?id=29915)
More... (http://www.news-medical.net/?id=29915)